Celldex Therapeutics, Inc. Share Price Nasdaq
Equities
US15117B1035
Biotechnology & Medical Research
Sales 2024 * | 3.39M 270M | Sales 2025 * | 3.13M 250M | Capitalization | 2.39B 191B |
---|---|---|---|---|---|
Net income 2024 * | -170M -13.57B | Net income 2025 * | -203M -16.2B | EV / Sales 2024 * | 622 x |
Net cash position 2024 * | 285M 22.77B | Net cash position 2025 * | 372M 29.73B | EV / Sales 2025 * | 646 x |
P/E ratio 2024 * |
-12.5
x | P/E ratio 2025 * |
-11.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 101.99% |
Latest transcript on Celldex Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Tibor Keler
FOU | Founder | 65 | 31/12/82 |
Anthony Marucci
FOU | Founder | 62 | 31/12/82 |
Sam Martin
DFI | Director of Finance/CFO | 53 | 31/03/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Herbert Conrad
BRD | Director/Board Member | 91 | 29/02/08 |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 15/06/22 |
Harry H. Penner
BRD | Director/Board Member | 78 | 31/12/96 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+48.71% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |